Back to search

Boston University

Multimodal analysis in normal aging, mild cognitive impairment, and Alzheimer's disease: group differentiation, baseline cognition, and prediction of future cognitive decline

Abstract

dc:description.abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease with an insidious onset that makes it difficult to distinguish from normal aging. It begins with an impairment of memory that develops into amnestic mild cognitive impairment (aMCI) and later to dementia as deficits become apparent in other cognitive domains. Effective biomarkers that differentiate normal aging, MCI, and AD and predict future cognitive decline are needed. Potential biomarkers have been studied in isolation, but their impact when combined is not understood. The goal of this project is to determine the optimal combination of CSF biomarkers, MRI morphometry, FDG PET metabolism, and neuropsychological test scores to differentiate between normal aging subjects and those with MCI and AD. This study addresses: 1) the optimal normalization region and partial volume correction method to quantify FDG PET analysis, 2) the effects of adjusting MRI-based cortical thickness measures for differences in gray/white matter tissue contrast in normal aging and disease, 3) whether multimodal multivariate stepwise logistic regression models can predict group membership, and 4) whether multimodal multivariate stepwise linear regression models can determine which imaging and CSF biomarker variables best predict future cognitive decline. The results indicate that normalizing FDG PET to the cerebellum along with using a gray matter mask for partial volume correction provides optimal prediction. In contrast, age-associated changes in gray/white matter intensity ratio did not differentiate between the groups and only slightly improved the efficacy of cortical thickness as a biomarker. MRI morphometry of the gray matter and neuropsychological test scores were better able to discriminate between the groups than FDG PET or CSF biomarker concentrations. Combining all modalities significantly improved the index of discrimination, especially at the earliest stages of the disease. MRI gray matter morphometry variables were more highly associated with baseline cognitive function and best predicted future cognitive decline compared to other variables. Overall these findings demonstrate that a multimodal approach using MRI morphometry, FDG PET metabolism, neuropsychological test scores, and CSF biomarkers provides significantly better discrimination than any modality alone. Hence, the variables important for discriminating between the groups may be candidates for biomarkers in human clinical interventional trials.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Anatomy and Neurobiology
Grantor dc:publisher
Boston University
Year dc:date.issued
2013

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bauer, Corinna Mae

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/10937

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Bauer, Corinna Mae. Multimodal analysis in normal aging, mild cognitive impairment, and Alzheimer's disease: group differentiation, baseline cognition, and prediction of future cognitive decline. doctoral thesis, Boston University, 2013. https://hdl.handle.net/2144/10937